We then stratified patients by breast cancer subtype, high-risk estrogen receptor (ER), and/or progesterone receptor (PgR)-positive/human epidermal growth factor receptor 2 (HER2)-negative versus triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.